Alzinova AB (publ)
Interim report Q2 2023

We will make it possible for Alzheimer's patients to live an independent and active life

Summary of the period January - June 2023

Highlights - second quarter

New positive interim data from the phase 1b study
– Demonstrated continued good safety and tolerability and clear immunological response.

Alzinova initiated extension part of the phase 1b study
– Aims to provide long-term data on immune response, safety and tolerability and the effect on biomarkers.

Preparation for phase 2 study
–Application submitted to FDA for pre-IND meeting (with positive feedback) and EMA for Scientific Advice.

Key figures from the period

Three months, April – June 2023

- Net sales amounted to SEK 0 (SEK 0)
- Loss after financial items amounted to SEK -3,928,458 (SEK -3,299,600)
- Average number of shares during the period before dilution 40,405,120 (16,387,646)
- Average number of shares during the period after dilution 40,619,993 (16,546,811)
- Earnings per share before dilution amounted to SEK -0.10 (SEK -0.20)
- Earnings per share after dilution amounted to SEK -0.10 (SEK -0.20)

Six months, January – June 2023

- Net sales amounted to SEK 0 (SEK 0)
- Loss after financial items amounted to SEK -8,199,961 (SEK -5,581,756)
- Average number of shares during the period before dilution 36,434,138 (16,176,845)
- Average number of shares during the period after dilution 36,649,011 (16,336,010)
- Earnings per share before dilution amounted to SEK -0.22 (SEK -0.34)
- Earnings per share after dilution amounted to SEK -0.22 (SEK -0.34)

Amounts in brackets: Corresponding period in previous year.
"the Company" or **"Alzinova"** refers to Alzinova AB with corporate identity number: 556861-8168.

Events during the second quarter 2023

- In April, the utilization period for the Company's series TO3 warrants commenced, with an exercise price set at 2.17 SEK per share and a subscription period from April 11th to April 21st. The warrants were exercised to a utilization rate equivalent to approximately 93.4%, resulting in the Company receiving approximately 26.3 million SEK before issuance costs.
- On April 12, Alzinova announced that all patients participating in the phase 1b study with the vaccine candidate ALZ-101 against Alzheimer's disease had received their fourth and final dose of the vaccine ALZ-101 or placebo.
- Alzinova announced on April 18 that the Company had received regulatory approval from the Finnish Medicines Agency, Fimea, and the Finnish National Ethics Committee to initiate an extension of the phase 1b study. The extension part aims to provide information on long-term safety and tolerability, immune response and also information on effects of ALZ-101 on biomarkers and cognitive functions.
- On April 24, Alzinova announced that the Company had terminated the agreement with Mangold Fondkommission AB on the assignment as liquidity provider. The last day for liquidity support trading of Mangold was April 28, 2023.
- On April 27, Alzinova announced a change in the management team, Chief Medical Officer (CMO) Anders Bylock will leave the Company for personal reasons, with his last day on May 28, 2023. The Company has previously initiated a recruitment process to find a replacement.
- On May 4, the Company announced that a second planned interim analysis was conducted of the ongoing clinical phase 1b study with the vaccine candidate ALZ-101 against Alzheimer's disease. The analysis showed positive data with continued good safety and tolerability and a clear immunological response, i.e. that specific antibodies have been formed following dosing with ALZ-101. Based on this positive second interim analysis, the Company made the decision to conduct an extension part of the study.
- On May 29, the Company announced that the extension part of the phase 1b study with the vaccine candidate ALZ-101 had been initiated by dosing the first patient.
- The Company convened an annual general meeting, which was held on May 30, 2023, and all proposed resolutions were adopted by the meeting. The minutes of the meeting are available on the Company's website, www.alzinova.com.

  At the AGM, Björn Larsson resigned as Chairman of the Board and the AGM thanked him for his far-reaching commitment and efforts during his 10 years as Chairman for Alzinova. Julian Aleksov was elected as the new Chairman of the Board.
- On June 13, the company announced that it has submitted an application for a pre-IND meeting with the US Food and Drug Administration (FDA) and an application for EMA Scientific Advice from the European Medicines Agency (EMA).

Events after the end of the second quarter 2023

- Alzinova announced on August 3 that the Company has recruited Kirsten Harting to the role of Chief Medical Officer (CMO). Kirsten Harting will be part of the Company's management team and will assume her position on August 14.
- On August 8, Alzinova announced that the Company has conducted a pre-IND meeting with the US FDA and received positive feedback on the planned clinical development program for the vaccine candidate ALZ-101.

A word from the CEO

The year has continued at a high pace with important events that have enabled us to reach several milestones. The development of our vaccine candidate ALZ-101 is proceeding according to plan with promising interim data that we obtained in May. Through regulatory agency interactions and partnering activities, we are working towards the goal of entering clinical phase 2 next year.

ALZ-101 vaccine - new positive interim data strengthens our position

The development of our vaccine candidate ALZ-101 is proceeding according to plan. In May, the second planned interim analysis was conducted in the clinical phase 1b study in Alzheimer's patients. The analysis again showed positive data with continued good safety and tolerability and a clear immunological response, i.e. that specific antibodies have been formed following dosing with ALZ-101. In addition, the new analysis showed that patients treated with ALZ-101 responded to treatment with antibody levels increasing with the number of doses given. We now look forward to topline data later in the year, likely during the fourth quarter.

Based on these positive data, we decided to initiate the extension part of the study and the first patient was dosed in May. The extension part will give us information about the immune response, safety and tolerability after a longer period of treatment. In addition, we have the opportunity to obtain information about the effect on biomarkers and cognitive functions. This is something that we believe further strengthens our position and is valuable for future interactions with potential partners and regulatory authorities.

Regulatory interactions ahead of phase 2

Based on the promising interim results with ALZ-101, we submitted an application for a pre-IND meeting with the US Food and Drug Administration (FDA) and an application for scientific advice from the European Medicines Agency (EMA).

During the summer, the meeting with the FDA was held where we received positive feedback on the planned clinical development program for the vaccine candidate ALZ-101. This validation of the quality of the project is a significant step for potential partner discussions, as well as the path towards the submission of an application to include US study centers in future phase 2 studies. We are now looking forward to receiving a response from the EMA in the autumn.

ALZ-101 and ALZ-201 with "best in class" potential

In June, the company participated in the major US biotech conference, BIO, held in Boston. BIO serves as an important forum for partnership meetings, where we presented our vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners. Attending BIO gave us an excellent opportunity to network, establish and deepen valuable contacts in the industry. We also had the chance to showcase our progress and innovations to a wide audience of experts and stakeholders. We are pleased to see significant interest in our vaccine. This is partly due to the positive progress seen with our specific approach and the benefits of using a vaccine as a treatment. Moreover, the amyloid hypothesis has been further strengthened by a third antibody, donanemab, showing positive phase 3 data. However, it is our oligomer-specific approach that sets us apart from the competition and gives us best-in-class potential.

Preparing the company for successful clinical development and future market introduction

The Company's organization has been further strengthened by our recruitment of Kirsten Harting as Chief Medical Officer with many years of experience in medicine, clinical trials and drug development as well as in business development and taking products to market.

Later this year, we will receive our long-awaited top-line data for the vaccine candidate ALZ-101. Based on all patients who participated in the study, it will give us an overall picture of

the safety and tolerability of treatment with ALZ-101 as well as information on the immune response for the two different dose levels 125 µg and 250 µg. We also hope to get an early indication of whether ALZ-101 has an effect on biological markers involved in the disease. During the autumn, we will continue to prepare for a new and exciting phase in Alzinova's history - through regulatory interactions and partnering activities with the goal of entering clinical phase 2 next year and taking the company to phase 3 readiness.

We look forward to sharing the continued journey with your shareholders!

Kristina Torfgård,
CEO of Alzinova AB

"During the autumn, we will continue to prepare for a new and exciting phase in Alzinova's history with the goal of entering clinical phase 2 next year."



About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's proprietary AβCC peptide technology™ enables the development of disease-modifying treatments that, with high precision, target the toxic accumulations of the peptide amyloid beta, so-called oligomers, which are central to the onset and progression of the disease. Using this technology, we can develop effective treatments which at the same time have a favourable safety profile with a lower risk of side effects. Promising preclinical results have been obtained following completion of a study on brain extracts from deceased Alzheimer's patients. The study confirms that Alzinova's unique method for specifically targeting and neutralizing toxic oligomers is effective.

Alzinova's current focus is the development of a vaccine that specifically targets and neutralizes the toxic oligomers. The vaccine is being developed as a long-acting drug for the treatment and prevention of Alzheimer's disease. The vaccine candidate ALZ-101 is in clinical development and a Phase 1b study in Alzheimer's patients was initiated in the third quarter of 2021 and fully recruited in December 2022. Based on positive interim data, the company decided in May 2023 to initiate an extension part of the ongoing clinical study. Top-line data is expected to be presented in the second half of 2023.

Based on the same technology, the Company is also developing the antibody, ALZ-201, which is currently in preclinical development. Alzinova is currently developing a humanized version of ALZ-201 for clinical phase 1 studies in patients with Alzheimer's disease. These studies are planned to start in 2024. The project portfolio for the development of disease-modifying treatments is broadened by the Company preparing the antibody to enter the clinical phase. Alzinova was founded by researchers who worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Alzinova's unique solution

- ✓ Targeted treatment that specifically targets and neutralizes the toxic peptides (so-called oligomers) that are central to the onset and development of Alzheimer's disease.
- ✓ Vaccine that stimulates the body to produce its own antibodies against oligomers (ALZ-101).
- ✓ Fast, effective and uncomplicated vaccination without long and expensive hospital stays.
- ✓ Specific treatment that is likely to have good efficacy and reduces the risk of serious side effects.
- ✓ Can start treatment early in the disease to prevent progression.
- ✓ Antibody (ALZ-201) that neutralizes the toxic oligomers and can be used as a stand-alone or as a complement to the vaccine (ALZ-101).

Other actors

- Are developing treatments that target larger accumulations of amyloid-beta, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- Non-specific treatments which are not specifically targeting and neutralizing the toxic oligomers.
- Often complicated drug treatments that require expensive hospital care.
- Targeting plaque is unlikely to be sufficiently effective and may result in serious side effects.





About Alzheimer

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous review.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease. The disease then increases sharply in prevalence in the 75-80 age range.

Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, and exhibit efficacy in patients with Alzheimer's. Based on clinical data, the Company intends to identify one or more strategic partners who can acquire projects for further development and commercialization. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or through a complete acquisition of the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more global pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. Furthermore, Alzinova has secured a scalable manufacturing process for ALZ-101, which is now being prepared for a phase 2 study so that a partner can quickly start phase 2. With positive results in the Company's two drug projects ALZ-101 and ALZ-201, there are several options. One is to out-license the vaccine ALZ-101 when the phase 1b study is complete, and another option is to take this further through phase 2 and then out-license it to a partner at the end of phase 2. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is precisely on business development with several active ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 percent. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at USD 1,300 billion annually. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs has recently been approved in the United States, there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential for a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India.

[1] World Health Organization (WHO) – Alzheimer's facts, September 2021.

Alzinova is developing a societal beneficial treatment



Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatment methods such as antibodies, only requires a few doses a year instead of as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increase societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive care.

Investment highlights

Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine to treat Alzheimer's disease. Positive interim data from the ongoing study demonstrate good safety and tolerability and a clear immunological response.

Based on the same unique technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a stand-alone or complementary treatment to the vaccine to combat Alzheimer's disease.

Data show that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) provides "best-in-class" potential, with ability to provide significantly better efficacy and a more favorable side effect.

Positive feedback from the FDA and other ongoing activities for the next phase of clinical development, together with strong IP, make Alzinova's candidates attractive for strategic partnerships.

Financial information

Corporate structure and shareholding

Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development

During the period April -June, the Company has continued to invest in the further development of ALZ-101, which is now in clinical phase 1b and for which also an extension of the study has been initiated. The Company has also initiated development for clinical trials of the antibody ALZ-201, with the aim of treating and also preventing the progression of Alzheimer's disease.

The Company's total expenses for the period April - June 2023 amounted to SEK 9.9 million (SEK 6.4 million same quarter last year). The majority of the costs, approximately SEK 6.0 million (compared to SEK 3.1 million for the same quarter last year), pertain to research and development expenses. Specifically, these costs are associated with the ongoing clinical trial, including the newly initiated extension phase that incurs initial higher expenses. The Company's research and development costs have been capitalized on the balance sheet. Personnel costs amounted to SEK 2.0 million (SEK 1.5 million same quarter last year). The higher costs are due to a planned and increased organization with more employees. Cash flow from operating activities during the period April - June 2023 amounted to SEK -4.9 million (SEK -7.2 million). For the period January - June 2023 in total, corresponding cash flow amounted to SEK -9.6 million (SEK-5.0 million).

The cash flow from the investment activities amounted during the period April - June 2023 to SEK -6.0 million (SEK -3.1 million). For the period January - June in total, corresponding cash flow amounted to SEK -10.7 million (SEK -10.0 million). The cash flow from the investment activities represents expenditure on ongoing capitalized research and development costs.

Cash flow from financing activities during the period April - June 2023 amounted to SEK 24.8 million (SEK 27.6 million), and during the period January - June 2023 corresponding cash flow amounted to SEK 24.8 million (SEK 30.3 million). The cash flow is constituted by shares from subscription warrants series TO3, attached in previous rights issue, which new shares were emitted in May and contributed with SEK 26.3 million before deduction of costs SEK -1.5 million.

At the end of the period (30 June, 2023), the Company's equity amounted to approximately SEK 122 million with an equity ratio of 96.4% (SEK 113 million and 96.5% respectively at 30 June, 2022), and total cash balance amounted to approximately SEK 37 million (SEK 44 million at 30 June, 2022).

Continuous work is underway on various financing options, to further strengthen the Company's financial position.

Risk factors

Alzinova maintains procedures to continuously identify and manage risk factors. A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2022.

Auditor's review

This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report

The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, August 17, 2023
Alzinova AB (publ)

Income statement

SEK	Apr-Jun 2023 3 months	Apr-Jun 2022 3 months	Jan-Jun 2023 6 months	Jan-Jun 2022 6 months	Jan-Dec 2022 12 months
Net sales	-	-	-	-	-
Own work capitalized	6,018,344	3,067,864	10,690,483	9,990,835	16,633,432
	6,018,344	**3,067,864**	**10,690,483**	**9,990,835**	**16,633,432**
Operating expenses					
Other external expenses	-7,889,848	-4,875,666	-14,881,036	-12,446,857	-23,032,905
Personnel expenses	-2,036,452	-1,489,758	-3,989,508	-3,117,027	-6,686,880
Operating result	**-3,907,956**	**-3,297,560**	**-8,180,061**	**-5,573,049**	**-13,086,353**
Result from financial items					
Interest income	273	-	875	-	17,905
Interest expenses	-20,775	-2,040	-20,775	-8,707	-19,401
Result after financial items	**-3,928,458**	**-3,299,600**	**-8,199,961**	**-5,581,756**	**-13,087,849**
Result before tax	**-3,928,458**	**-3,299,600**	**-8,199,961**	**-5,581,756**	**-13,087,849**
Result for the period	**-3,928,458**	**-3,299,600**	**-8,199,961**	**-5,581,756**	**-13,087,849**

Balance sheet

SEK	30 June 2023	30 June 2022	31 December 2022
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	87,339,143	70,006,062	76,648,660
Patent	1,632,086	1,632,086	1,632,086
	88,971,229	**71,638,148**	**78,280,746**
Total fixed assets	**88,971,229**	**71,638,148**	**78,280,746**
Current assets			
Short term receivables			
Tax receivables	190,060	138,604	205,684
Other receivables	616,583	829,826	630,186
Prepaid expenses and accrued income	379,991	545,610	466,784
	1,186,634	**1,514,040**	**1,302,654**
Cash and cash receivables	**36,580,059**	**44,060,070**	**32,037,675**
Total current assets	**37,766,693**	**45,574,110**	**33,340,329**
TOTAL ASSETS	**126,737,922**	**117,212,258**	**111,621,075**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	11,711,723	8,526,206	8,526,206
Fund for development costs	85,276,028	67,937,216	74,585,545
	96,987,751	**76,463,422**	**83,111,751**
Unrestricted equity			
Share premium	166,264,090	144,752,332	144,644,792
Retained result	-132,913,809	-102,487,148	-109,135,477
Results for the year/period	-8,199,961	-5,581,756	-13,087,849
	25,150,320	**36,683,428**	**22,421,466**
Total equity	**122,138,071**	**113,146,850**	**105,533,217**
Long term liabilities			
Other long term liabilities	800,000	800,000	800,000
	800,000	**800,000**	**800,000**
Short term liabilities			
Accounts payable	1,925,194	1,433,988	3,170,435
Other current liabilities	203,298	575,416	722,782
Accrued expenses and prepaid income	1,671,359	1,256,004	1,394,641
	3,799,851	**3,265,408**	**5,287,858**
TOTAL EQUITY AND LIABILITIES	**126,737,922**	**117,212,258**	**111,621,075**

Change in equity, condensed

Jan - Jun 2023 6 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**8,526,206**	**74,585,545**	**144,644,792**	**-122,223,326**	**105,533,217**
Share issue	3,185,517		23,098,024		26,283,541
Transaction costs share issue			-1,478,726		-1,478,726
Transfer within equity		10,690,483		-10,690,483	0
Net result for the period				-8,199,961	-8,199,961
At the end of the period	**11,711,723**	**85,276,028**	**166,264,090**	**-141,113,770**	**122,138,071**

January - June 2022 6 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**
Share issue	4,377,191		32,482,459		36,859,650
Transaction costs share issue			-6,602,803		-6,602,803
Transfer within equity		9,990,830		-9,990,830	0
Net result for the period				-5,581,756	-5,581,756
At the end of the period	**8,526,206**	**67,937,216**	**144,752,332**	**-108,068,904**	**113,146,850**

Jan - Dec 2022 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the period	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**
Share issue	4,377,191		32,482,459		36,859,650
Transaction costs share issue			-6,710,343		-6,710,343
Transfer within equity		16,639,159		-16,639,159	0
Net result for the year				-13,087,849	-13,087,849
At the end of the year	**8,526,206**	**74,585,545**	**144,644,792**	**-122,223,326**	**105,533,217**

Cash flow statement, condensed

SEK	Apr - Jun 2023 3 months	Apr - Jun 2022 3 months	Jan - Jun 2023 6 months	Jan - Jun 2022 6 months	Jan - Dec 2022 12 months
Operating activities					
Result after financial items	-3,928,458	-3,299,600	-8,199,961	-5,581,756	-13,087,849
Adjustments for items not included in cash flow	-	-	-	-	-
Cash flow from operating activities before change in working capital	**-3,928,458**	**-3,299,600**	**-8,199,961**	**-5,581,756**	**-13,087,849**
Cash flow from change in working capital					
Increase (-)/Decrease (+) in operating receivables	238,856	307,800	116,020	-305,498	-94,112
Increase (+)/Decrease (-) in operating liabilities	-1,204,177	-4,257,431	-1,488,007	845,775	2,868,225
Cash flow from operating activities	**-4,893,779**	**-7,249,231**	**-9,571,948**	**-5,041,479**	**-10,313,736**
Investing activities					
Acquisition of intangible fixed assets	-6,018,344	-3,067,864	-10,690,483	-9,990,835	-16,633,433
Cash flow from investing activities	**-6,018,344**	**-3,067,864**	**-10,690,483**	**-9,990,835**	**-16,633,433**
Financing activities					
Share issue	26,283,541	34,039,983	26,283,541	36,859,650	36,859,650
Transaction costs share issue	-1,478,726	-6,439,320	-1,478,726	-6,602,803	-6,710,343
Cash flow from financing activities	**24,804,815**	**27,600,663**	**24,804,815**	**30,256,847**	**30,149,307**
Cash flow for the period	**13,892,692**	**17,283,568**	**4,542,384**	**15,224,533**	**3,202,138**
Cash and cash equivalents at the beginning of the period	**22,687,367**	**26,776,502**	**32,037,675**	**28,835,537**	**28,835,537**
Cash and cash equivalents at the end of the period	**36,580,059**	**44,060,070**	**36,580,059**	**44,060,070**	**32,037,675**

The share

Alzinova's share was listed on the Spotlight Stock Market on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of June 30, 2023, the number of shares in Alzinova amounted to 44,531,265 (32,419,034 as of June 30, 2022).

Share-based incentive programs

The Company's CEO and other senior executives as well as parts of the board, has through a long-term incentive program, held a total of 159,165 warrants of series 2020/2023, which entitle them to subscribe for an equal number of shares during the period June 1 - July 31, 2023. After recalculation due to result from previous rights issues carried out after issuance of the subscription warrants, the adjusted price was set at SEK 16.60/share (initially SEK 22.50/share) and the number of shares per subscription warrant was set at 1.35 (initially 1 share per option). During the subscription period no holder of subscription warrants signed for new shares. If the warrants had been fully exercised, it had, as per the balance day 30 June, 2023, corresponded to a dilution of the number of shares and votes in the Company of approximately 0.5%.

Rights issue

During the period April - June 2022, the Company carried out a rights issue with attached warrants of the series TO3. During the subscription period for the warrants (11-25 April, 2023) in total 12,112,231 warrants were exercised, resulting in a subscription rate of approximately 93.4%. The subscription meant that the Company's shares increased during this second quarter by 12,112,231 shares to a total of 44,531,265 shares and with a total share capital of SEK 11,711,723. In total, a net of approximately SEK 24.8 million was added to the Company after deduction of around SEK 1.5 million of issue costs. For shareholders who did not exercise their warrants, the dilution amounts to approximately 27.2% based on the total number of shares in the Company.

Largest owners per June 30, 2023

Shareholder	No. of shares	Capital %
Maida vale Capital AB	6,747,686	15.15%
Försäkrings AB Avanza pension	3,430,328	7.70%
Nordnet pensionsförsäkring AB	1,850,535	4.16%
Patrik Ahlvin	1,004,750	2.26%
Ålandsbanken, för ägare	927,061	2.08%
Sara Gjertz	898,553	2.02%
MIVAC Development AB	711,787	1.60%
MGC Capital Ltd	604,171	1.36%
Moll Invest AB	600,080	1.35%
Marcus Milerud	461,000	1.03%
Total 10 largest shareholders	**17,235,951**	**38.71%**
Total other shareholders	27,295,314	61.29%
Total all shareholders	**44,531,265**	**100.00%**

Financial calendar

2023

Interim report 1, 2023	2023-05-17
Annual general meeting 2023	2023-05-30
Interim report 2, 2023	2023-08-17
Interim report 3, 2023	2023-11-02
Year-end report, 2023	2024-02-28

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

For further information, please contact:

Kristina Torfgård, CEO, kristina.torfgard@alzinova.com, telephone +46 708 467975
Håkan Skogström, CFO, hakan.skogstrom@alzinova.com, telephone +46 705 850859
or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
Donanemab	Monoclonal antibody being developed by Lilly for the treatment of Alzheimer's disease.
DSMB	Data Safety and Monitoring Board
EMA	European Medicines Agency
FDA	The United States Food and Drug Administration
IP	Intellectual properties, for example patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Neurotoxic	Dangerous or poisonous to the brain
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42
Pre-IND meeting	Regulatory advice from the FDA regarding product development programs

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Pepparedsleden 1, SE-431 83,
Mölndal, Sweden

alzinova